Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines

References

• World Health Organization. WHO Coronavirus disease (COVID-19) dashboard. [accessed 2022 Nov 4]. https://covid19.who.int.
   Google Scholar
• Mallapaty S, Callaway E, Kozlov M, Ledford H, Pickrell J, Van Noorden R. How COVID vaccines shaped 2021 in eight powerful charts. Nature. 2021;600(7890):580–16. doi:10.1038/d41586-021-03686-x.
   PubMed Web of Science ®Google Scholar
• Dolgin E. Omicron thwarts some of the world’s most-used COVID vaccines. Nature. 2022;601(7893):311. doi:10.1038/d41586-022-00079-6.
   PubMed Web of Science ®Google Scholar
• J. H. Tracking coronavirus vaccinations around the world. The New York Times. [accessed 2022 Jul 12]. https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html.
   Google Scholar
• World Health Organization. WHO - prequalification of medical products (IVDs, medicines, vaccines and immunization devices, vector control). COVID-19 vaccines with WHO Emergency Use Listing. [accessed 2022 Jun 16]. https://extranet.who.int/pqweb/vaccines/vaccinescovid-19-vaccine-eul-issued.
   Google Scholar
• Shrotri M, Swinnen T, Kampmann B, Parker EPK. An interactive website tracking COVID-19 vaccine development. Lancet Glob Health. 2021;9(5):e590–92. doi:10.1016/s2214-109x(21)00043-7.
   PubMed Web of Science ®Google Scholar
• COVID-19 Vaccine Tracker. Equity of vaccine roll-out. [accessed 2022 Jun 16]. https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/.
   Google Scholar
• World Health Organization. WHO recommendation COVID-19 vaccine Beijing Institute of Biological Products Co., Ltd. (BIBP)/Sinopharm. [accessed 2022 Jul 12]. https://extranet.who.int/pqweb/vaccines/who-recommendation-covid-19-vaccine-bibp.
   Google Scholar
• World Health Organization. COVID-19 vaccines with WHO emergency use listing. [accessed 2022 Jul 12]. https://extranet.who.int/pqweb/vaccines/vaccinescovid-19-vaccine-eul-issued/.
   Google Scholar
• European Medicines Agency. Heterologous primary and booster COVID-19 vaccination: evidence based regulatory considerations. [accessed 2022 Jul 6]. https://www.ema.europa.eu/en/documents/report/heterologous-primary-booster-covid-19-vaccination-evidence-based-regulatory-considerations_en.pdf.
   Google Scholar
• Cheng H, Peng Z, Si S, Alifu X, Zhou H, Chi P, Zhuang Y, Mo M, Yu Y. Immunogenicity and safety of homologous and heterologous prime–boost immunization with COVID-19 vaccine: systematic review and meta-analysis. Vaccines (Basel). 2022;10(5):798. doi:10.3390/vaccines10050798.
   PubMed Web of Science ®Google Scholar
• Au WY, Cheung PP. Effectiveness of heterologous and homologous COVID-19 vaccine regimens: living systematic review with network meta-analysis. BMJ. 2022;377:e069989. doi:10.1136/bmj-2022-069989.
   PubMedGoogle Scholar
• Ministério da Saúde. Secretaria Extraordinária de Enfrentamento à COVID-19 Gabinete. NOTA TÉCNICA Nº 11/2022-SECOVID/GAB/SECOVID/MS. Nota Técnica que tem por objetivo de consolidar as Notas Técnicas referentes a vacinação da população maior de 12 anos. [accessed 2022 Jun 14]. https://www.gov.br/saude/pt-br/coronavirus/vacinas/plano-nacional-de-operacionalizacao-da-vacina-contra-a-covid-19/notas-tecnicas/2022/nota-tecnica-no11.pdf/view.
   Google Scholar
• Subsecretaría de Salud Pública División de Prevención y Control de Enfermedades Departamento de Inmunizaciones. Tercera dosis de vacuna contra SARS-COV-2 EN pacientes pediátricos inmunocomprometidos (3-11 años). [accessed 2022 Jun 14]. https://www.minsal.cl/wp-content/uploads/2022/02/Tercera-dosis-de-vacuna-contra-SARS-CoV-2-en-pacientes-pedi%C3%A1tricos-inmunocomprometidos-3-11-a%C3%B1os.pdf.
   Google Scholar
• World Health Organization. Interim recommendations for heterologous COVID-19 vaccine schedules. [accessed 2022 Jul 6]. https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-vaccines-SAGE-recommendation-heterologous-schedules.
   Google Scholar
• Centers for Disease Control and Prevention. Summary document for interim clinical considerations for use of COVID-19 vaccines currently authorized or approved in the United States. [accessed 2022 Jul 12]. https://www.cdc.gov/vaccines/covid-19/downloads/summary-interim-clinical-considerations.pdf.
   Google Scholar
• Angkasekwinai N, Niyomnaitham S, Sewatanon J, Phumiamorn S, Sukapirom K, Senawong S, Toh ZQ, Umrod P, Somporn T, Chumpol S, et al. The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdox1 nCov-19 primary series. medRxiv. 2022. doi:10.1101/2021.11.29.21266947.
   Google Scholar
• Leung NHL, Cheng SMS, Martín-Sánchez M, Au NYM, Ng YY, Luk LLH, Chan KCK, JKC L, Leung YWY, Tsang LCH, et al. Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine. Clin Infect Dis. 2022. doi:10.1093/cid/ciac458.
   Web of Science ®Google Scholar
• Assawakosri S, Kanokudom S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Duangchinda T, Chantima W, Pakchotanon P, et al. Neutralizing activities against the Omicron variant after a heterologous booster in healthy adults receiving two doses of CoronaVac vaccination. J Infect Dis. 2022;226(8):1372–81. Epub ahead of print. doi:10.1093/infdis/jiac092.
   PubMed Web of Science ®Google Scholar
• Campos GRF, Almeida NBF, Filgueiras PS, Corsini CA, Gomes SVC, de Miranda DAP, de Assis JV, de Souza Silva TB, Alves PA, da Rocha Fernandes G, et al. Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant. Commun Med. 2022;2:(1):76. doi:10.1038/s43856-022-00141-4.
   PubMedGoogle Scholar
• Cerqueira-Silva T, Katikireddi SV, de Araujo Oliveira V, Flores-Ortiz R, Júnior JB, Paixão ES, Robertson C, Penna GO, Werneck GL, Barreto ML, et al. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nat Med. 2022;28:(4):838–43. doi:10.1038/s41591-022-01701-w.
   PubMed Web of Science ®Google Scholar
• Cheng SMS, Mok CKP, Leung YWY, Ng SS, Chan KCK, Ko FW, Chen C, Yiu K, Lam BHS, Lau EHY, et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med. 2022;28:(3):486–89. doi:10.1038/s41591-022-01704-7.
   PubMed Web of Science ®Google Scholar
• Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV, da Guarda SNF, de Nobrega MM, de Moraes Pinto MI, Gonzalez IGS, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022;399:(10324):521–29. doi:10.1016/s0140-6736(22)00094-0.
   PubMed Web of Science ®Google Scholar
• Grenfell RFQ, Almeida NB, Filgueiras PS, Corsini CA, Gomes SV, de Miranda DA, Lourenço AJ, Martins Filho OA, de Oliveira JG, Teixeira-Carvalho A. Immunogenicity, effectiveness, and safety of inactivated virus (CoronaVac) vaccine in a two-dose primary protocol and BNT162b2 heterologous booster in Brazil (Immunita-001): a one year period follow up phase 4 study. Front Immunol. 2022;13:918896. doi:10.2139/ssrn.4070408.
   PubMed Web of Science ®Google Scholar
• Hayashi JY, Simizo A, Miyamoto JG, Costa LVS, Souza OF, Chiarelli T, Bacarov NBS, Hidalgo R, Garcia LD, Soane MM, et al. Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdox1 and heterologous third dose with BNT162b2. J Infect. 2022;84:(6):834–72. doi:10.1016/j.jinf.2022.02.026.
   PubMed Web of Science ®Google Scholar
• Hueda-Zavaleta M, Gómez de la Torre JC, Cáceres-Del Aguila JA, Muro-Rojo C, De La Cruz-Escurra N, Arenas Siles D, Minchón-Vizconde D, Copaja-Corzo C, Bardales-Silva F, Benites-Zapata VA, et al. Evaluation of the humoral immune response of a heterologous vaccination between BBIBP-CorV and BNT162b2 with a temporal separation of 7 months, in Peruvian healthcare workers with and without a history of SARS-CoV-2 infection. Vaccines (Basel). 2022;10:(4):502. doi:10.3390/vaccines10040502.
   PubMed Web of Science ®Google Scholar
• Jara A, Undurraga EA, Zubizarreta JR, Gonzalez C, Pizarro A, Acevedo J, Leo K, Paredes F, Bralic T, Vergara V. Effectiveness of homologous and heterologous booster shots for an inactivated SARS-CoV-2 vaccine: a large-scale observational study. 2022. Epub ahead of print. doi:10.2139/ssrn.4005130
   Google Scholar
• Keskin AU, Bolukcu S, Ciragil P, Topkaya AE. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. J Med Virol. 2022;94(1):39–41. doi:10.1002/jmv.27350.
   PubMed Web of Science ®Google Scholar
• Kuloglu ZE, El R, Guney-Esken G, Tok Y, Talay ZG, Barlas T, Kuskucu MA, Albayrak O, Dogan O, Yavuz SS, et al. Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: a longitudinal study. Allergy. 2022;77(8):2459–67. Epub ahead of print. doi:10.1111/all.15316.
   PubMed Web of Science ®Google Scholar
• Lai KT, Wan Loong EY L, Fung TL, Luk LW, Lau CC, Zee JS, Ma ES, Tang BS. Safety and immunogenicity of a booster vaccination by CoronaVac or BNT162b2 in previously two-dose inactivated virus vaccinated individuals with negative neutralizing antibody. Vaccines (Basel). 2022;10(4):556. doi:10.3390/vaccines10040556.
   PubMed Web of Science ®Google Scholar
• Matula Z, Gonczi M, Beko G, Kadar B, Ajzner E, Uher F, Valyi-Nagy I. Antibody and T cell responses against SARS-CoV-2 elicited by the third dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNtech) vaccines using a homologous or heterologous booster vaccination strategy. Vaccines (Basel). 2022;10(4):539. doi:10.3390/vaccines10040539.
   PubMed Web of Science ®Google Scholar
• Moghnieh R, Mekdashi R, El-Hassan S, Abdallah D, Jisr T, Bader M, Jizi I, Sayegh MH, Rahman Bizri A. Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: results of a pilot prospective cohort study from Lebanon. Vaccine. 2021;39(46):6713–19. doi:10.1016/j.vaccine.2021.10.007.
   PubMed Web of Science ®Google Scholar
• Niyomnaitham S, Quan Toh Z, Wongprompitak P, Jansarikit L, Srisutthisamphan K, Sapsutthipas S, Jantraphakorn Y, Mingngamsup N, Licciardi PV, Chokephaibulkit K. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: an open-label randomized study in healthy Thai adults. Hum Vaccin Immunother. 2022;18(6):2091865. doi:10.1080/21645515.2022.2091865.
   PubMed Web of Science ®Google Scholar
• Patamatamkul S, Thammawat S, Buranrat B. Induction of robust neutralizing antibodies against the COVID-19 Delta variant with ChAdox1 nCov-19 or BNT162b2 as a booster following a primary vaccination series with CoronaVac. medRxiv. 2021. doi:10.1101/2021.09.25.21264099.
   Google Scholar
• Pérez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, Vogels CBF, Malik AA, De la Cruz E, Jorge A, et al. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nat Med. 2022;28:(3):481–85. doi:10.1038/s41591-022-01705-6.
   PubMed Web of Science ®Google Scholar
• Mok CKP, Chen C, Yiu K, Chan TO, Lai KC, Ling KC, Sun Y, Hui DS, Cheng SMS, Peiris M. A randomized clinical trial using CoronaVac or BNT162b2 vaccine as a third dose in adults vaccinated with two doses of CoronaVac. Am J Respir Crit Care Med. 2022;205(7):844–47. doi:10.1164/rccm.202111-2655LE.
   PubMed Web of Science ®Google Scholar
• Ranzani OT, Hitchings MD, de Melo RL, de França GV, de Fátima RF C, Lind ML, Torres MSS, Tsuha DH, David LC, Said RF. Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against the Omicron (B. 1.1. 529) variant. medRxiv. 2022. doi:10.1101/2022.03.30.22273193.
   Google Scholar
• Sritipsukho P, Khawcharoenporn T, Siribumrungwong B, Damronglerd P, Suwantarat N, Satdhabudha A, Chaiyakulsil C, Sinlapamongkolkul P, Tangsathapornpong A, Bunjoungmanee P, et al. Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study. Emerg Microbes Infect. 2022;11:(1):585–92. doi:10.1080/22221751.2022.2037398.
   PubMed Web of Science ®Google Scholar
• Yavuz E, Gunal O, Basbulut E, Sen A. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine. J Med Virol. 2022;94(8):3768–75. doi:10.1002/jmv.27794.
   PubMed Web of Science ®Google Scholar
• Suah JLB, Tng BHP, Keng Tok PM, Husin MM, Thevananthan TB, Peariasamy KMM, Sivasampu SM. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection. Emerg Microbes Infect. 2022;11(1):1–17. doi:10.1080/22221751.2022.2072773.
   PubMed Web of Science ®Google Scholar
• Vargas-Herrera N, Fernández-Navarro M, Cabezudo NE, Soto-Becerra P, Solís-Sánchez G, Escobar-Ágreda S, Silva-Valencia J, Pampa-Espinoza L, Bado-Pérez R, Solari L, et al. Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru. medRxiv. 2022. doi:10.1101/2022.05.01.22274548.
   Google Scholar
• Demirhindi H, Mete B, Tanir F, Kara E, Kibar F, Cetiner S, Candevir A, Akti SE. Effect of heterologous vaccination strategy on humoral response against COVID-19 with CoronaVac plus BNT162b2: a prospective cohort study. Vaccines (Basel). 2022;10(5):687. doi:10.3390/vaccines10050687.
   PubMed Web of Science ®Google Scholar
• Jantarabenjakul W, Sodsai P, Chantasrisawad N, Jitsatja A, Ninwattana S, Thippamom N, Ruenjaiman V, Tan CW, Pradit R, Sophonphan J, et al. Dynamics of neutralizing antibody and T-cell responses to SARS-CoV-2 and variants of concern after primary immunization with CoronaVac and booster with BNT162b2 or ChAdox1 in health care workers. Vaccines (Basel). 2022;10:(5):639. doi:10.3390/vaccines10050639.
   PubMed Web of Science ®Google Scholar
• Liwsrisakun C, Pata S, Laopajon W, Takheaw N, Chaiwong W, Inchai J, Pothirat C, Bumroongkit C, Deesomchok A, Theerakittikul T, et al. Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdox-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine. Immun Ageing. 2022;19:(1):24. doi:10.1186/s12979-022-00279-8.
   PubMed Web of Science ®Google Scholar
• Marra AR, Miraglia JL, Malheiros DT, Guozhang Y, Teich VD, da Silva Victor E, Pinho JRR, Cypriano A, Vieira LW, Polonio M, et al. Effectiveness of heterologous coronavirus disease 2019 (COVID-19) vaccine Booster Dosing in Brazilian healthcare workers, 2021. Clin Infect Dis. 2022. Epub ahead of print. doi:10.1093/cid/ciac430.
   Google Scholar
• Suntronwong N, Kanokudom S, Auphimai C, Assawakosri S, Thongmee T, Vichaiwattana P, Duangchinda T, Chantima W, Pakchotanon P, Chansaenroj J, et al. Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination. medRxiv. 2022. doi:10.1101/2022.04.25.22274294.
   Google Scholar
• Zhang B, Huo J, Huang Y, Teo SY, Li YF, Toh LK, Lam K-P, Xu S. mRNA booster vaccination enhances antibody responses against SARS-CoV2 Omicron variant in individuals primed with mRNA or inactivated virus vaccines. Res Square. 2022. Preprint. doi:10.21203/rs.3.rs-1577475/v1.
   Google Scholar
• Zuo F, Abolhassani H, Du L, Piralla A, Bertoglio F, de Campos-Mata L, Wan H, Schubert M, Cassaniti I, Wang Y, et al. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat Commun. 2022;13:(1):2670. doi:10.1038/s41467-022-30340-5.
   PubMed Web of Science ®Google Scholar
• Kanokudom S, Assawakosri S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Yorsaeng R, Srimuan D, Thatsanatorn T, et al. Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine. Vaccines (Basel). 2022;10:(1):86. doi:10.3390/vaccines10010086.
   PubMed Web of Science ®Google Scholar
• Shaw RH, Stuart A, Greenland M, Liu X, Van-Tam JS N, Snape MD. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021;397(10289):2043–46. doi:10.1016/s0140-6736(21)01115-6.
   PubMed Web of Science ®Google Scholar
• Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med. 2022;386:(11):1046–57. doi:10.1056/NEJMoa2116414.
   PubMed Web of Science ®Google Scholar
• Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdox1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398(10318):2258–76. doi:10.1016/s0140-6736(21)02717-3.
   PubMed Web of Science ®Google Scholar
• Liu X, Munro APS, Feng S, Janani L, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, et al. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdox1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial. J Infect. 2022;84:(6):795–813. doi:10.1016/j.jinf.2022.04.018.
   PubMed Web of Science ®Google Scholar
• Pagliari M, Mazzetto E, Gastaldelli M, Bortolami A, Donà D, Padoan A, Di Chiara C, Pezzani MD, Cosma C, Napolitan A, et al. Omicron neutralization and the inference of correlates of protection based on anti-SARS-CoV-2 S-RBD IgG levels in boosted individuals. SSRN Electron J. 2022. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4016530.
   Google Scholar
• UK Health Security Agency. COVID-19 vaccine surveillance report: week 9. Department of Health and Social Care. [accessed 2022 Jul 8]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf.
   Google Scholar
• Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdox1 nCov-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis. 2022;22:(8):1131–41. doi:10.1016/s1473-3099(22)00271-7.
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, Gower C, Kall M, Groves N, O’Connell AM, et al. COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386:(16):1532–46. doi:10.1056/NEJMoa2119451.
   PubMed Web of Science ®Google Scholar
• Chemaitelly H, Abu-Raddad LJ. Waning effectiveness of COVID-19 vaccines. Lancet. 2022;399(10327):771–73. doi:10.1016/s0140-6736(22)00277-x.
   PubMed Web of Science ®Google Scholar
• Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, Lewis N, Natarajan K, Stenehjem E, Grannis SJ, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION network, 10 states, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:(7):255–63. doi:10.15585/mmwr.mm7107e2.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Abu-Raddad LJ, Andrews N, Davies MA, Higdon MM, Orenstein WA, Patel MK. Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization. Vaccine. 2022;40(26):3516–27. doi:10.1016/j.vaccine.2022.04.069.
   PubMed Web of Science ®Google Scholar
• Arbel R, Hammerman A, Sergienko R, Friger M, Peretz A, Netzer D, Yaron S. BNT162b2 vaccine booster and mortality due to Covid-19. N Engl J Med. 2021;385(26):2413–20. doi:10.1056/NEJMoa2115624.
   PubMed Web of Science ®Google Scholar
• Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V, Zaccardi F, Khunti K, Alwan NA, Walker AS. Trajectory of long covid symptoms after COVID-19 vaccination: community based cohort study. BMJ. 2022;377:e069676. doi:10.1136/bmj-2021-069676.
   PubMedGoogle Scholar
• Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, Rescigno M. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA. 2022;328(7):676. doi:10.1001/jama.2022.11691.
   PubMed Web of Science ®Google Scholar
• Holm M, Espenhain L, Glenthøj J, Schmidt LS, Nordly SB, Hartling UB, Nygaard U. Risk and phenotype of multisystem inflammatory syndrome in vaccinated and unvaccinated Danish children before and during the Omicron wave. JAMA Pediatr. 2022;176(8):821. doi:10.1001/jamapediatrics.2022.2206.
   PubMed Web of Science ®Google Scholar
• Napuri NI, Curcio D, Swerdlow DL, Srivastava A. Immune response to COVID-19 and mRNA vaccination in immunocompromised individuals: a narrative review. Infect Dis Ther. 2022;11(4):1391–414. doi:10.1007/s40121-022-00648-2.
   PubMed Web of Science ®Google Scholar
• Kirson N, Swallow E, Lu J, Mesa-Frias M, Bookhart B, Maynard J, Shivdasani Y, Lefebvre P. The societal economic value of COVID-19 vaccines in the United States. J Med Econ. 2022;25(1):119–28. doi:10.1080/13696998.2022.2026118.
   PubMed Web of Science ®Google Scholar
• Premikha M, Chiew CJ, Wei WE, Leo YS, Ong B, Lye DC, Lee VJ, Tan KB. Comparative effectiveness of mRNA and inactivated whole virus vaccines against COVID-19 infection and severe disease in Singapore. Clin Infect Dis. 2022;75(8):1442–45. doi:10.1093/cid/ciac288.
   PubMed Web of Science ®Google Scholar
• Singapore Ministry of Health. FAQS - safety and efficacy of the COVID-19 vaccine. [accessed 2022 Aug 15]. https://www.moh.gov.sg/covid-19/vaccination/faqs—safety-and-efficacy-of-the-covid-19-vaccine.
   Google Scholar
• US Food & Drug Administration. Coronavirus (COVID-19) update: FDA limits use of Janssen COVID-19 vaccine to certain individuals. [accessed 2022 Jun 16]. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-janssen-covid-19-vaccine-certain-individuals.
   Google Scholar
• UNICEF. COVAX: ensuring global equitable access to COVID-19 vaccines. [accessed 2022 Jul 19]. https://www.unicef.org/supply/covax-ensuring-global-equitable-access-covid-19-vaccines.
   Google Scholar
• UNICEF. COVID-19 vaccine market dashboard. [accessed 2022 Jul 19]. https://www.unicef.org/supply/covid-19-vaccine-market-dashboard.
   Google Scholar